173 related articles for article (PubMed ID: 14657626)
1. Flow-cytometric DNA analysis in cutaneous fibrohistiocytic tumors.
Okita H; Ohtsuka T; Yamazaki S
Dermatology; 2003; 207(4):357-61. PubMed ID: 14657626
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibrosarcoma protuberans: an analysis of proliferative activity, DNA flow cytometry and p53 overexpression with emphasis on its progression.
Sasaki M; Ishida T; Horiuchi H; MacHinami R
Pathol Int; 1999 Sep; 49(9):799-806. PubMed ID: 10504551
[TBL] [Abstract][Full Text] [Related]
3. Flow cytometric DNA analysis of malignant fibrous histiocytoma and related fibrohistiocytic tumors.
Radio SJ; Wooldridge TN; Linder J
Hum Pathol; 1988 Jan; 19(1):74-7. PubMed ID: 2826327
[TBL] [Abstract][Full Text] [Related]
4. Phosphohistone-H3 and Ki67: Useful Markers in Differentiating Dermatofibroma From Dermatofibrosarcoma Protuberans and Atypical Fibrohistiocytic Lesions.
Agarwal A; Gopinath A; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2017 Jul; 39(7):504-507. PubMed ID: 28609344
[TBL] [Abstract][Full Text] [Related]
5. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin.
Wang WL; Patel KU; Coleman NM; Smith-Zagone MJ; Ivan D; Reed JA; López-Terrada D; Lazar AJ; Prieto VG
Am J Dermatopathol; 2010 Apr; 32(2):149-53. PubMed ID: 19940748
[TBL] [Abstract][Full Text] [Related]
6. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications.
Worrell JT; Ansari MQ; Ansari SJ; Cockerell CJ
J Cutan Pathol; 1993 Jun; 20(3):211-5. PubMed ID: 8396160
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical markers in fibrohistiocytic lesions: factor XIIIa, CD34, S-100 and p75.
West KL; Cardona DM; Su Z; Puri PK
Am J Dermatopathol; 2014 May; 36(5):414-9. PubMed ID: 24162384
[TBL] [Abstract][Full Text] [Related]
8. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
9. [Fibrohistiocytic tumors of the skin: a heterogeneous group of superficially located mesenchymal neoplasms].
Mentzel T
Pathologe; 2015 Feb; 36(1):79-88. PubMed ID: 25589356
[TBL] [Abstract][Full Text] [Related]
10. Atypical fibroxanthoma versus benign and malignant fibrous histiocytoma. A comparative study of their proliferative activity using MIB-1, DNA flow cytometry, and p53 immunostaining.
Oshiro Y; Fukuda T; Tsuneyoshi M
Cancer; 1995 Mar; 75(5):1128-34. PubMed ID: 7850711
[TBL] [Abstract][Full Text] [Related]
11. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
12. Angiomatoid features in fibrohistiocytic sarcomas. Immunohistochemical, ultrastructural, and clinical distinction from vascular neoplasms.
Costa MJ; McGlothlen L; Pierce M; Munn R; Vogt PJ
Arch Pathol Lab Med; 1995 Nov; 119(11):1065-71. PubMed ID: 7487409
[TBL] [Abstract][Full Text] [Related]
13. Nucleolar organizer regions in fibrohistiocytic tumors of the skin.
Merot Y; Durgniat AC; Frenk E
J Cutan Pathol; 1990 Apr; 17(2):122-6. PubMed ID: 1692574
[TBL] [Abstract][Full Text] [Related]
14. Clonal analysis of cutaneous fibrous histiocytoma (dermatofibroma).
Hui P; Glusac EJ; Sinard JH; Perkins AS
J Cutan Pathol; 2002 Aug; 29(7):385-9. PubMed ID: 12139632
[TBL] [Abstract][Full Text] [Related]
15. Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors.
Koga K; Nabeshima K; Nishimura N; Shishime M; Nakayama J; Iwasaki H
Eur J Dermatol; 2005; 15(6):465-9. PubMed ID: 16280300
[TBL] [Abstract][Full Text] [Related]
16. [Differences of the molecular phenotypes and the histogenesis between dermatofibroma and dermatofibrosarcoma protuberans].
Xiong Y; Guo H; Zhang S; Zhang B; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 40(4):395-400. PubMed ID: 18677387
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous soft tissue tumors: how do we make sense of fibrous and "fibrohistiocytic" tumors with confusing names and similar appearances?
Hornick JL
Mod Pathol; 2020 Jan; 33(Suppl 1):56-65. PubMed ID: 31653978
[TBL] [Abstract][Full Text] [Related]
18. Molecular biological observations in some rare neoplasms: DNA ploidy and cell cycle data in liposarcoma and malignant fibrous histiocytoma.
Lüdemann M; Fischer A; Finke M; Wolff-Vorbeck G; Böhm J; Imdahl A
Langenbecks Arch Surg; 1999 Apr; 384(2):209-15. PubMed ID: 10328177
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of platelet-derived growth factor and its receptors in fibrohistiocytic tumors.
Taniuchi K; Yamada Y; Nonomura A; Takehara K
J Cutan Pathol; 1997 Aug; 24(7):393-7. PubMed ID: 9274955
[TBL] [Abstract][Full Text] [Related]
20. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
